Freenome

Closed (deSPAC)

Profile in progress

What it is: Freenome is an early cancer detection company developing blood-based tests to detect cancer when it is most treatable
What it’s doing now: Merging with Perceptive Capital Solutions Corp (PCSC) — closed (despac).
What you should know: Data is still being assembled for this company — what is shown below is everything we have verified so far.

The business, per its filings

SEC primary

Freenome is an early cancer detection company developing blood-based tests to detect cancer when it is most treatable. The company recognizes that no single technology can identify every cancer due to the disease’s inherent heterogeneity. Freenome’s approach combines a multiomics platform that analyzes multiple signals in the blood with artificial intelligence and machine learning to tune into cancer’s subtlest clues, even at the earliest stages of the disease.

What the company says about itself

Web research — not audited

Freenome is developing blood-based screening tests designed to detect cancer at its earliest, most treatable stages. The company combines multiomics, artificial intelligence, and machine learning in its Personalized Cancer Detection approach. Its portfolio of SimpleScreen blood-based screening tests includes SimpleScreen CRC as its first offering.

Markets:: cancer detection | healthcare | biotechnology | medical diagnostics
Products:: SimpleScreen CRC | Personalized Cancer Detection platform

What our web check found

[WEB-INTEL 2026-08-26] 6 finding(s) · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "The transaction includes commitments for a common equity PIPE at $10.00 per share of approximately $240 million" [https://www.prnewswire.com/news-releases/freenome-and-perceptive-capital-solutions-corp-announce-business-combination-agreement-to-create-a-publicly-listed-company-transforming-blood-based-multi-cancer-detection-through-an-aiml-enabled-multiomics-platform-302634039.html] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "In addition to approximately $90 million held in PCSC's trust account (assuming no redemptions by PCSC's public shareholders)" [https://www.prnewswire.com/news-releases/freenome-and-perceptive-capital-solutions-corp-announce-business-combination-agreement-to-create-a-publicly-listed-company-transforming-blood-based-multi-cancer-detection-through-an-aiml-enabled-multiomics-platform-302634039.html] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Freenome expects to receive approximately $330 million (prior to the payment of transaction costs and assuming no redemptions by PCSC's public shareholders). The proceeds will be funded through a combination of approximately $90 million hel" [https://www.prnewswire.com/news-releases/freenome-and-perceptive-capital-solutions-corp-announce-business-combination-agreement-to-create-a-publicly-listed-company-transforming-blood-based-multi-cancer-detection-through-an-aiml-enabled-multiomics-platform-302634039.html] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Assuming no redemptions by PCSC's public shareholders, the combined company is expected to have a post-transaction equity value of approximately $1.1 billion at closing." [https://www.prnewswire.com/news-releases/freenome-and-perceptive-capital-solutions-corp-announce-business-combination-agreement-to-create-a-publicly-listed-company-transforming-blood-based-multi-cancer-detection-through-an-aiml-enabled-multiomics-platform-302634039.html] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Business combination is expected to be completed in the first half of 2026" [https://www.prnewswire.com/news-releases/freenome-and-perceptive-capital-solutions-corp-announce-business-combination-agreement-to-create-a-publicly-listed-company-transforming-blood-based-multi-cancer-detection-through-an-aiml-enabled-multiomics-platform-302634039.html] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Freenome and PCSC outlined a SPAC merger with a $240M PIPE, ~$92M trust cash and an expected $525M pro forma cash balance" [https://www.stocktitan.net/sec-filings/PCSC/425-perceptive-capital-solutions-corp-business-combination-communicat-fbc3978c8141.html]

Source: https://www.freenome.com/ · captured Aug 26, 2026 · marketing claims are reported as claims, never merged into the filed figures above.

The deal it’s entering

Freenome is merging with Perceptive Capital Solutions Corp (PCSC) currently marked Closed (deSPAC).

Headline equity value	—
PIPE	≈ $240M · unsourced

Structure per SEC accession(s) 0001140361-26-017428. How to read these numbers: headline vs effective valuation · what a definitive agreement commits

What exactly is being valued, and at what

Common questions

Is Freenome going public?

Freenome has an approved merger with the SPAC Perceptive Capital Solutions Corp (PCSC). Deal status: Closed (deSPAC).

Does Freenome have revenue?

The filings we've parsed don't state a usable revenue figure yet; this profile is updated as new documents land.

Educational content, not investment advice.